ULURU Inc. (OTCMKTS:ULUR) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01
ULURU Inc. (OTCMKTS:ULUR) Files An 8-K Changes in Registrant’s Certifying Accountant
Changes in Registrant’s Certifying Accountant
The Audit Committee of the Board of Directors of ULURU Inc. (the “Company”) approved the engagement of Montgomery Coscia Greilich LLP (“MCG”) to serve as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the years ending December 31, 2016 and 2017 as well as to perform review services in regards to the quarterly financial information of the Company included in its Quarterly Reports on Form 10-Q for 2017. On January 4, 2017, MCG formally advised the Company that effective as of such date it was accepting the position as the Company’s independent registered public accounting firm.
During the years ended December 31, 2016 and 2015, and the interim period through January 4, 2017, neither the Company nor anyone acting on its behalf consulted with MCG regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was the subject of a disagreement (as described in Item 304(a)(1)(iv) or reportable event (as described in Item 304(a)(1)(v)) of Regulation S-K.
About ULURU Inc. (OTCMKTS:ULUR)
ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores. ULURU Inc. (OTCMKTS:ULUR) Recent Trading Information
ULURU Inc. (OTCMKTS:ULUR) closed its last trading session down -0.0001 at 0.0399 with 1,026 shares trading hands.
ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores. ULURU Inc. (OTCMKTS:ULUR) Recent Trading Information
ULURU Inc. (OTCMKTS:ULUR) closed its last trading session down -0.0001 at 0.0399 with 1,026 shares trading hands.